Levetiracetam
- Generic Name
- Levetiracetam
- Brand Names
- Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O2
- CAS Number
- 102767-28-2
- Unique Ingredient Identifier
- 44YRR34555
- Background
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...
- Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...
- Associated Conditions
- Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
- Associated Therapies
- -
Comparison of Keppra and Clonidine in the Treatment of Tics
- Conditions
- Interventions
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2011-09-07
- Lead Sponsor
- Harvey S. Singer
- Target Recruit Count
- 12
- Registration Number
- NCT00370838
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- UCB Japan Co. Ltd.
- Target Recruit Count
- 398
- Registration Number
- NCT00367432
A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy
- Conditions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2011-07-28
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT00361010
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸The Cleveland Clinic, Cleveland, Ohio, United States
The Effects of Levetiracetam on Alcohol Dependent Subjects
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Boston University
- Target Recruit Count
- 40
- Registration Number
- NCT00325182
- Locations
- 🇺🇸
Boston University Dept of Psychiatry Clinical Studies Unit, Boston, Massachusetts, United States
Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 600
- Registration Number
- NCT00319605
Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease
- Conditions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 34
- Registration Number
- NCT00307450
- Locations
- 🇩🇪
Department of Neurology at the Technical University of Dresden, Dresden, Germany
🇩🇪Department of Neurology at the University of Leipzig, Leipzig, Germany
Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder
- Conditions
- Interventions
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Duke University
- Target Recruit Count
- 12
- Registration Number
- NCT00299611
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2007-11-15
- Lead Sponsor
- 1st Hospital of Social Security Services
- Target Recruit Count
- 50
- Registration Number
- NCT00291733
- Locations
- 🇬🇷
Department of Neurology, 1st Hospital of Social Security Services, Athens, Greece
Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 130
- Registration Number
- NCT00291655
Levetiracetam Treatment of Tardive Dyskinesia
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT00291213
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.